NCT02547987View on ClinicalTrials.gov

Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 1, 2015

Primary Completion Date

June 25, 2019

Study Completion Date

September 30, 2025

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6

DRUG

Carboplatin

Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6

Trial Locations (3)

45242

TriHealth Hatton Research, Cincinnati

77030

Lester & Sue Smith Breast Center at Baylor College of Medicine, Houston

77054

Harris Health System Smith Clinic, Houston

All Listed Sponsors
lead

Mothaffar Rimawi

OTHER